Sugi Predict

Sugi Predict / Targets / MCL1

MCL1

Induced myeloid leukemia cell differentiation protein Mcl-1 · Q07820 · MCL1 on Sugi Atlas →

325,874 patent compounds predicted against MCL1, 202,262 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Gossypol Gossypol (SCHEMBL3939) 1.00 12/20
SCHEMBL78479 SCHEMBL78479 0.44 9/20
Diflunisal Diflunisal (SCHEMBL4337) 0.53 8/20
SCHEMBL67766 SCHEMBL67766 0.53 8/20
SCHEMBL66378 SCHEMBL66378 0.45 8/20
Umbelliferone Umbelliferone (SCHEMBL22018) 1.00 7/20
SCHEMBL23277 SCHEMBL23277 0.72 7/20
SCHEMBL78583 SCHEMBL78583 0.55 7/20
SCHEMBL78662 SCHEMBL78662 0.55 7/20
Athraquinones A Athraquinones A (SCHEMBL18614) 1.00 6/20
Esculetin Esculetin (SCHEMBL24641) 1.00 6/20
Fraxetin Fraxetin (SCHEMBL43472) 1.00 6/20
SCHEMBL84570 SCHEMBL84570 0.50 6/20
SCHEMBL70164 SCHEMBL70164 0.66 5/20
Mesalamine Mesalamine (SCHEMBL31297) 0.65 5/20
Purpurin Purpurin (SCHEMBL33871) 0.63 5/20
Psoralen Psoralen (SCHEMBL17835) 0.55 5/20
SCHEMBL63131 SCHEMBL63131 0.34 5/20
Coumarin Coumarin (SCHEMBL6252) 1.00 4/20
Coumarin Coumarin (SCHEMBL73511) 0.83 4/20

Clinical trials — most relevant to MCL1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia PHASE3COMPLETED
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) PHASE3RECRUITING
PD-1 Inhibitors +Venetoclax+CAG Regimens in R/R T-ALL PHASE3ACTIVE_NOT_RECRUITING
A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloid Leukemia PHASE2NOT_YET_RECRUITING
Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma PHASE1/PHASE2NOT_YET_RECRUITING
A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma PHASE2RECRUITING
Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia PHASE2RECRUITING
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant PHASE1/PHASE2RECRUITING
Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML PHASE1/PHASE2COMPLETED
Study of Azacitidine Combined With Homoharringtonie Based Regimens in AML PHASE2UNKNOWN
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia PHASE2ACTIVE_NOT_RECRUITING
Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML PHASE1/PHASE2WITHDRAWN
NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL) PHASE2COMPLETED
Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL PHASE2ACTIVE_NOT_RECRUITING
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia PHASE1/PHASE2COMPLETED
Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma PHASE1/PHASE2WITHDRAWN
Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML PHASE1RECRUITING
Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome PHASE1COMPLETED
PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome PHASE1COMPLETED
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN PHASE1ACTIVE_NOT_RECRUITING
Dietary Intervention With High Phenolic EVOO in CLL nanCOMPLETED
Clinical Study Protocol of Maintenance Therapy With Venetoclax in Elderly Patients With AML in First Complete Remission nanRECRUITING
Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML nanRECRUITING
Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA. nanRECRUITING
Obatoclax Mesylate in Samples From Young Patients With Acute Myeloid Leukemia nanCOMPLETED
Association of CD49d and CD44 in CLL Patients and Their Role in Prognosis nanUNKNOWN
Study of Biomarkers in Blood and Bone Marrow Samples From Patients With Previously Untreated Chronic Lymphocytic Leukemia nanCOMPLETED
Mesenchymal Stem Cells in NPM1 Mutated Low Risk Acute Myeloid Leukemia: a Study of the Tumor Microenvironment and Its Contribution to the Outcome nanCOMPLETED
Don't Eat me Signal in Hematological Malignancies: CD24 as New Target to Improve Anti-cancer Immunity. nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a MCL1 binder may also engage these)

ProteinNameSimilarity
Q7YRZ9 — 1.000 Q7YRZ9 →
Q8HYS5 — 1.000 Q8HYS5 →
Q9Z1P3 — 1.000 Q9Z1P3 →
P97287 — 1.000 P97287 →
Q17QK1 — 0.992 Q17QK1 →
P60571 — 0.992 P60571 →
Q5BIR3 — 0.991 Q5BIR3 →
Q8TBC3 — 0.990 Q8TBC3 →
G5EGA3 — 0.990 G5EGA3 →
F5HB62 — 0.990 F5HB62 →
Q99PI5 — 0.990 Q99PI5 →
P19091 — 0.989 P19091 →
O46080 — 0.989 O46080 →
Q2PFD7 — 0.989 Q2PFD7 →
Q91ZP6 — 0.989 Q91ZP6 →
Q8JZP9 — 0.989 Q8JZP9 →
Q7RTV3 — 0.989 Q7RTV3 →
Q5VVW2 — 0.989 Q5VVW2 →
Q6NN85 — 0.989 Q6NN85 →
Q80WL2 — 0.989 Q80WL2 →
Q96RD6 — 0.989 Q96RD6 →
G5EEC5 — 0.988 G5EEC5 →
A7MB27 — 0.988 A7MB27 →
BPTF Nucleosome-remodeling factor subunit BPTF 0.988 landscape →
Q9Z0Y7 — 0.988 Q9Z0Y7 →
Q7ZUL9 — 0.988 Q7ZUL9 →
P11299 — 0.988 P11299 →
Q9S7P5 — 0.988 Q9S7P5 →
Q9BQK8 — 0.988 Q9BQK8 →
Q96PX1 — 0.988 Q96PX1 →